Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AMLJoshua F. Zeidner, Alice S. Mims, Kristin L Koenig et al.|Journal of Clinical Oncology|2025Cited by 36
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W. Hoff, Yazan F. Madanat, William Blum et al.|Blood Advances|2024Cited by 29